Short Interest in RedHill Biopharma Ltd. (NASDAQ:RDHL) Decreases By 17.6%

RedHill Biopharma Ltd. (NASDAQ:RDHL) was the recipient of a significant decline in short interest in November. As of November 30th, there was short interest totalling 5,600 shares, a decline of 17.6% from the November 15th total of 6,800 shares. Based on an average trading volume of 22,800 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.4% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on RedHill Biopharma in a research report on Saturday, August 24th. They issued a “hold” rating on the stock.

RedHill Biopharma Price Performance

NASDAQ:RDHL traded down $0.28 on Monday, reaching $7.16. 9,074 shares of the company’s stock were exchanged, compared to its average volume of 106,060. RedHill Biopharma has a 52 week low of $6.34 and a 52 week high of $43.50. The stock has a fifty day simple moving average of $7.82 and a 200-day simple moving average of $107.24.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.